FeesSafety
Pluang+

Opera's desktop users hit 100M MAUs with Q3 revenue up 20%, signaling strong growth and AI integration progress.

Company Fundamentals
03 Nov 2026, 15:00 WIB
PRNewsWire
View Source
Bullish
Opera's desktop users hit 100M MAUs with Q3 revenue up 20%, signaling strong growth and AI integration progress.

Opera Limited announced its desktop browser reached 100 million monthly active users in October 2026, marking a 16% year-over-year increase. The company reported Q3 2026 revenue of $182.8 million, a 20% rise from the previous year, and adjusted EBITDA of $43.2 million, exceeding guidance. This growth is driven by innovative product releases and AI integration, positioning Opera as a strong alternative to default browsers. Full Q3 results will be released on November 17, with a conference call scheduled to discuss details.

Opera Limited's Q3 2026 revenue reached $182.8 million, a 20% increase year-over-year, with adjusted EBITDA of $43.2 million exceeding guidance. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 03, 2026 19:11 WIB: out of 150 priced US tech stocks, 76 rose and 73 fell. Notable movers include KLAC at USD 157.80 (+3.06%, 77% Sell / 23% Buy), EXFY at USD 2.36 (+3.06%), and ASX at USD 38.01 (-2.96%, 53% Sell / 47% Buy).

More News

Automatic FOUP Opener Market to reach $6.04B by 2032 with 5.36% CAGR driven by fab automation and contamination control

Automatic FOUP Opener Market to reach $6.04B by 2032 with 5.36% CAGR driven by fab automation and contamination control

The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...

Market News
Bullish
21 minutes ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
3 hours ago
Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
3 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
3 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App